Company: DNLI
Filing Date: 2025-04-17
Form Type: DEF 14A
Source: 0001714899-25-000087
Chunk: 78

Company: Denali Therapeutics Inc.
Filing Date: 2025-04-17
Form: DEF 14A
Chunk 78
---
 current executive officers and directors as a group.

We have determined beneficial ownership in accordance with the rules of the SEC and the information is not necessarily indicative of beneficial ownership for any other purpose. Unless otherwise indicated below, to our knowledge, the persons and entities named in the table have sole voting and sole investment power with respect to all shares that they beneficially owned, subject to community property laws where applicable.

We have based our calculation of the percentage of beneficial ownership on 145,227,767 shares of our common stock outstanding as of March 31, 2025. We have deemed shares of our common stock subject to RSU lapses or stock options that are currently exercisable or exercisable within 60 days of March 31, 2025, to be outstanding and to be beneficially owned by the person holding the stock option for the purpose of computing the percentage ownership of that person. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person.

<div align='center'>-59-</div>

Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080.

| Name of Beneficial Owner                                                                    |     | Number of    
 Shares       
 Beneficially 
 Owned        |            |     | Percentage   
 of Shares    
 Beneficially 
 Owned        |      |   |
| 5% Stockholders:                                                                            |     |              |            |     |              |      |   |
| BlackRock(1)                                                                                |     |              | 13,787,873 |     |              |  9.5 | % |
| Baillie Gifford & Co(2)                                                                     |     |              | 12,313,931 |     |              |  8.5 | % |
| Vanguard Group(3)                                                                           |     |              | 10,834,483 |     |              |  7.5 | % |
| Wellington(4)                                                                               |     |              | 10,727,450 |     |              |  7.4 | % |
| FMR LLC(5)                                                                                  |     |              | 10,141,901 |     |              |  7.0 | % |
| Named Executive Officers, Directors, and Director Nominees:                                 |     |              |            |     |              |      |   |
| Ryan J.